We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Molecular Test for HPVs Uses Standard Diagnostic Equipment

By Biotechdaily staff writers
Posted on 19 Nov 2007
A DNA-based diagnostic test for human papillomavirus (HPV) uses standard molecular diagnostic equipment found in most commercial laboratories. More...
The HPV DNA test complements a HPV blood test being developed to detect the presence of antibodies produced by cancer-causing HPV types.

There are some 100 types of HPV; however, only about 7-15 HPV-types cause most cervical cancers. Grant Life Sciences, a developer of diagnostic testing systems, believes that a blood-based test to detect precancerous evidence and cancer of the cervix is the preferred test-methodology to address the needs of the developing world. Molecular (DNA) testing is currently the approved test protocol in both the United States and Europe to identify the presence of different subtypes of HPV in the cervix.

An agreement has been signed by Grant Life Sciences, Inc. (Salt Lake, UT, USA) and Alphagenics Diaco Biotechnologies S.r.l. (Trieste, Italy) to exclusively in-license the manufacturing and marketing rights to the Alphagenics' molecular diagnostic test for human papillomaviruses (HPVs) in China and the United States and non-exclusively in all other countries.

The introduction of the Alphagenics HPV test not only will allow commercial laboratories to provide molecular testing but will also complement the current introduction of vaccines against HPVs, according to Dr. Hun-Chi Lin, president and chief scientist, Grant Life Sciences.

In addition, Dr. Lin said that the Alphagenics test could be used in the current gynecologic regimen to help qualify Pap test results in the case of ambiguous readings, at a cost less than the currently approved molecular test. Grant Life expects to launch the Alphagenics HPV DNA-based test in the Asian and Indian markets during the first quarter of 2008 as an Analyte-Specific Reagent (ASR) to reference laboratories.

Alphagenics Diaco Biotechnologies is one of the most specialized companies in Italy in the use of technical innovation in molecular biology for the production of kits for clinical and research use in oncology, bacteriology, virology, and mycology.

Grant Life Sciences engages in research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers.


Related Links:
Grant Life Sciences
Alphagenics Diaco Biotechnologies S.r.l.

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Manual Pipetting Aid
Pipette Controllers macro
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.